Neuroprotective effects of a selective N-methyl-D-aspartate NR2b receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 11, 2008, Pages 1388-1394

  Leaver, K R ^a   Allbutt, H N ^a   Creber, N J ^a   Kassiou, M ^b,c   Henderson, J M ^a  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Animal model; Neuroprotection; NR2B N methyl D aspartate (NMDA) receptor; Parkinson's disease; Substantia nigra

Indexed keywords

4 TRIFLUOROMETHOXY N (2 TRIFLUOROMETHYLBENZYL)BENZAMIDINE; BZAD 01; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN PROTECTION; CELL LOSS; CIRCLING BEHAVIOR; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; FEMALE; HEAD POSITION; IMMUNOHISTOCHEMISTRY; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PREMEDICATION; RAT; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANIMALS; BENZAMIDINES; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 54249111876     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05046.x     Document Type: Conference Paper

References (29)

1. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2004 102 : 155 74.
2. Przuntek H, Welzel D, Gerlach M et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J. Neural Transm. 1996 103 : 699 715.
3. Eslamboli A, Baker HF, Ridley RM, Annett LE. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Exp. Neurol. 2003 183 : 418 29.
4. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr. Drug Targets 2001 2 : 241 71.
5. Loopuijt LD, Schmidt WJ. The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Amino Acids 1998 14 : 17 23.
6. Loftis JM, Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: Localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003 97 : 55 85.
7. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003 14 : 404 16.
8. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-d-aspartate (NMDA) receptors in pain: A review. Anesth. Analg. 2003 97 : 1108 16.
9. Tzschentke TM. Glutamatergic mechanisms in different disease states: Overview and therapeutical implications. An introduction. Amino Acids 2002 23 : 147 52.
10. Loschmann PA, De Groote C, Smith L et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol. 2004 187 : 86 93.
11. Nash JE, Brotchie JM. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov. Disord. 2002 17 : 455 66.
12. Chenard BL, Menniti FS. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharmaceut. Des. 1999 5 : 381 404.
13. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101 606 exacerbates l-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of l-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 2004 188 : 471 9.
14. Claiborne CF, McCauley JA, Libby BE et al. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 2003 13 : 697 700.
15. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 1996 50 : 275 331.
16. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego. 1998.
17. Truong L, Allbutt H, Kassiou M, Henderson JM. Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res. 2006 169 : 1 9.
18. Allbutt HN, Henderson JM. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J. Neurosci. Meth. 2007 159 : 195 202.
19. Henderson JM, Watson S, Halliday GM, Heinemann T, Gerlach M. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav. Brain Res. 2003 139 : 105 13.
20. Fearnley JML, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991 114 : 2283 301.
21. Carman LS, Gage FH, Shults CW. Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior. Brain Res. 1991 553 : 275 83.
22. Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 2003 91 : 9 18.
23. Mengual E, de las Heras S, Erro E, Lanciego JL, Gimenez-Amaya JM. Thalamic interaction between the input and the output systems of the basal ganglia. J. Chem. Neuroanat. 1999 16 : 187 200.
24. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: Clinical and therapeutic implications. Brain 2000 123 : 1410 21.
25. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000 23 (Suppl S64 70.
26. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann. Neurol. 2001 49 : 525 9.
27. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioural and immunohistochemical studies. Eur. J. Neurosci. 1996 8 : 1408 14.
28. Jones S, Gibb AJ. Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J. Physiol. 2005 569 : 209 21.
29. Oh JD, Russell DS, Vaughan CL, Chase TN. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and l-DOPA administration. Brain Res. 1998 820 : 150 9.